Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (MSCLF)
OTHER OTC:MSCLF
MSCLF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.27 - $0.94
Previous CloseN/A
Volume2.00K
Average Volume (3M)47.02K
Market Cap
$82.59M
Enterprise Value$67.78M
Total Cash (Recent Filing)C$1.92M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Jun 03, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding153,375,400
10 Day Avg. Volume57,064
30 Day Avg. Volume47,015
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.86Price Target Upside68.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Satellos Bioscience News
PremiumCompany Announcements
Satellos Bioscience to Engage with Investors at April Conferences
PremiumCompany Announcements
Satellos Bioscience Advances DMD Therapy with Promising Trial Results
PremiumCompany Announcements
Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference
PremiumCompany Announcements
Satellos Completes Phase 1 Enrollment for DMD Drug Trial
PremiumCompany Announcements
Satellos Bioscience to Showcase at Oppenheimer Healthcare Conference---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 1a data demonstrated that SAT-3247 was safe and well-tolerated across multiple dosage levels.
Future ProspectsThe upcoming data readout is expected to include preliminary results on pharmacodynamic markers and muscle function, which could provide further validation.
Bears Say
Financial PerformanceThe company reported no revenue, in line with the consensus estimate, and a net loss.
RisksRisks identified include clinical, regulatory, commercial, competition, and dilution.
---
Options Prices
Currently, No data available
---
Ownership Overview
MSCLF FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was $0.27 and its highest was $0.94 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is $82.59M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Jun 03, 2025 which is in 62 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Mar 26, 2025. The company reported -$0.042 earnings per share for the quarter, missing the consensus estimate of -$0.029 by -$0.013.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.03.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 153,375,400 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -$0.042 in its last earnings report, missing expectations of -$0.029. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in MSCLF
---
Satellos Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.86 (68.63% Upside)
$0.86 (68.63% Upside)
Insider Transactions
Bought Shares
Worth $43.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.54%
12-Months-Change
Fundamentals
Return on Equity
-52.63%
Trailing 12-Months
Asset Growth
51.12%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
---
MSCLF Stock 12 Month Forecast
Average Price Target
$0.86
▲(68.63% Upside)
Technical Analysis
Best Analysts Covering MSCLF
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+23.64%
reiterated a buy rating 7 days ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +23.64% per trade.
---